Pernix Therapeutics Holdings Company Profile (NASDAQ:PTX)

About Pernix Therapeutics Holdings (NASDAQ:PTX)

Pernix Therapeutics Holdings logoPernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:PTX
  • CUSIP: 71426V10
  • Web:
  • Market Cap: $45.77 million
  • Outstanding Shares: 10,015,000
Average Prices:
  • 50 Day Moving Avg: $4.28
  • 200 Day Moving Avg: $3.80
  • 52 Week Range: $1.83 - $10.40
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $138.13 million
  • Price / Sales: 0.33
  • Book Value: ($14.26) per share
  • Price / Book: -0.31
  • EBIDTA: $1.79 million
  • Net Margins: -125.33%
  • Return on Assets: -36.64%
  • Debt-to-Equity Ratio: -0.83%
  • Current Ratio: 0.88%
  • Quick Ratio: 0.79%
  • Average Volume: 418,002 shs.
  • Beta: 1.69
  • Short Ratio: 12.27

Frequently Asked Questions for Pernix Therapeutics Holdings (NASDAQ:PTX)

What is Pernix Therapeutics Holdings' stock symbol?

Pernix Therapeutics Holdings trades on the NASDAQ under the ticker symbol "PTX."

How were Pernix Therapeutics Holdings' earnings last quarter?

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) posted its quarterly earnings results on Monday, May, 15th. The company reported ($2.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.80) by $1.86. The business had revenue of $29.74 million for the quarter. View Pernix Therapeutics Holdings' Earnings History.

Who are some of Pernix Therapeutics Holdings' key competitors?

Who are Pernix Therapeutics Holdings' key executives?

Pernix Therapeutics Holdings' management team includes the folowing people:

  • John A. Sedor, Chairman of the Board, Chief Executive Officer
  • Graham G. Miao Ph.D., President, Chief Financial Officer, Director
  • Kenneth Robert Pina, Senior Vice President, Chief Compliance Officer, General Counsel
  • Michael Joseph Golembiewski, Vice President, Corporate Controller, Principal Accounting Officer
  • Dennis H. Langer M.D., J.D., Independent Director
  • Gabriel S. Leung, Independent Director
  • Tasos G Konidaris, Non-Executive Independent Director

How do I buy Pernix Therapeutics Holdings stock?

Shares of Pernix Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pernix Therapeutics Holdings' stock price today?

One share of Pernix Therapeutics Holdings stock can currently be purchased for approximately $4.49.

MarketBeat Community Rating for Pernix Therapeutics Holdings (NASDAQ PTX)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  196 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about Pernix Therapeutics Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pernix Therapeutics Holdings (NASDAQ:PTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Pernix Therapeutics Holdings (NASDAQ:PTX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/12/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
3/23/2016S&P Equity ResearchLower Price Target$1.37 -> $1.12N/AView Rating Details
3/16/2016Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
3/10/2016Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
3/2/2016JMP SecuritiesLower Price TargetMarket Outperform$8.00 -> $6.00N/AView Rating Details
(Data available from 7/21/2015 forward)


Earnings History for Pernix Therapeutics Holdings (NASDAQ:PTX)
Earnings by Quarter for Pernix Therapeutics Holdings (NASDAQ:PTX)
Earnings History by Quarter for Pernix Therapeutics Holdings (NASDAQ PTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($4.80)($2.94)$29.74 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.60)($2.99)$48.60 million$41.50 millionViewN/AView Earnings Details
8/11/2016Q2($0.08)($0.47)$46.98 million$36.75 millionViewListenView Earnings Details
5/5/2016Q116($0.06)($0.42)$44.55 million$32.50 millionViewN/AView Earnings Details
3/10/2016Q4$0.01($0.59)$47.95 million$46.37 millionViewListenView Earnings Details
11/5/2015Q315$0.01$0.08$46.83 million$48.60 millionViewN/AView Earnings Details
8/6/2015Q215($0.01)($0.10)$50.70 million$47.00 millionViewN/AView Earnings Details
5/1/2015Q115$0.04($0.11)$34.55 million$33.90 millionViewN/AView Earnings Details
2/25/2015Q414$0.18$0.25$52.70 million$53.00 millionViewN/AView Earnings Details
11/10/2014Q314($0.02)$28.10 million$31.50 millionViewN/AView Earnings Details
8/11/2014Q214($0.05)($0.16)$26.20 million$17.40 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.26)$23.65 million$19.10 millionViewN/AView Earnings Details
3/17/2014Q413($0.10)($0.15)$23.82 million$23.90 millionViewN/AView Earnings Details
11/12/2013Q3($0.13)($0.16)$23.06 million$18.30 millionViewListenView Earnings Details
8/9/2013Q2 2013($0.13)($0.16)$20.82 million$20.60 millionViewN/AView Earnings Details
5/10/2013Q1 2013$0.02($0.05)ViewN/AView Earnings Details
11/14/2012Q312$0.03($0.01)$15.04 million$18.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pernix Therapeutics Holdings (NASDAQ:PTX)

No earnings estimates for this company have been tracked by


Dividend History for Pernix Therapeutics Holdings (NASDAQ:PTX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Pernix Therapeutics Holdings (NASDAQ:PTX)
Insider Ownership Percentage: 5.62%
Institutional Ownership Percentage: 17.34%
Insider Trades by Quarter for Pernix Therapeutics Holdings (NASDAQ:PTX)
Institutional Ownership by Quarter for Pernix Therapeutics Holdings (NASDAQ:PTX)
Insider Trades by Quarter for Pernix Therapeutics Holdings (NASDAQ:PTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/19/2015Sanjay S PatelCFOBuy5,000$4.60$23,000.00View SEC Filing  
8/18/2015Douglas DrysdaleCEOBuy8,500$4.69$39,865.00View SEC Filing  
5/6/2015Douglas DrysdaleCEOBuy16,000$6.40$102,400.00View SEC Filing  
5/6/2015Sanjay S PatelCFOBuy2,000$6.42$12,840.00View SEC Filing  
11/3/2014Tracy Simmons CliffordInsiderSell2,246$10.00$22,460.00View SEC Filing  
10/28/2014Tracy Simmons CliffordInsiderSell12,754$10.00$127,540.00View SEC Filing  
5/21/2014James Edward Jr. Smithmajor shareholderSell194,600$6.13$1,192,898.00View SEC Filing  
5/16/2014James Edward Jr. Smithmajor shareholderSell310,200$6.12$1,898,424.00View SEC Filing  
5/14/2014James Edward Jr. Smithmajor shareholderSell289,400$5.47$1,583,018.00View SEC Filing  
5/9/2014James Edward Jr. Smithmajor shareholderSell45,000$4.37$196,650.00View SEC Filing  
5/6/2014James Edward Jr. Smithmajor shareholderSell45,000$4.44$199,800.00View SEC Filing  
5/1/2014James Edward Jr. Smithmajor shareholderSell30,000$4.68$140,400.00View SEC Filing  
4/29/2014James Edward Jr. Smithmajor shareholderSell30,000$4.88$146,400.00View SEC Filing  
4/25/2014James Edward Jr. Smithmajor shareholderSell30,000$5.20$156,000.00View SEC Filing  
4/24/2014James Edward Jr. Smithmajor shareholderSell30,000$4.94$148,200.00View SEC Filing  
4/17/2014James Edward Jr. Smithmajor shareholderSell20,000$4.35$87,000.00View SEC Filing  
4/15/2014James Edward Jr. Smithmajor shareholderSell45,000$4.63$208,350.00View SEC Filing  
4/10/2014James Edward Jr. Smithmajor shareholderSell45,000$5.03$226,350.00View SEC Filing  
4/7/2014James Edward Jr. Smithmajor shareholderSell45,000$4.90$220,500.00View SEC Filing  
4/2/2014Cooper CollinsInsiderSell90,000$5.26$473,400.00View SEC Filing  
4/2/2014James Edward Jr. Smithmajor shareholderSell45,000$5.26$236,700.00View SEC Filing  
3/28/2014James Edward Jr. Smithmajor shareholderSell45,000$5.47$246,150.00View SEC Filing  
3/25/2014James Edward Jr. Smithmajor shareholderSell255,000$4.21$1,073,550.00View SEC Filing  
3/4/2014Cooper CollinsInsiderSell3,590,000$3.40$12,206,000.00View SEC Filing  
2/5/2014Cooper Collinsmajor shareholderSell90,000$2.22$199,800.00View SEC Filing  
1/7/2014Cooper Collinsmajor shareholderSell27,962$2.20$61,516.40View SEC Filing  
1/6/2014Cooper Collinsmajor shareholderSell62,038$2.35$145,789.30View SEC Filing  
12/6/2013Cooper Collinsmajor shareholderSell37,452$2.31$86,514.12View SEC Filing  
12/4/2013Cooper Collinsmajor shareholderSell52,548$2.44$128,217.12View SEC Filing  
11/5/2013Cooper C CollinsMajor ShareholderSell90,000$2.01$180,900.00View SEC Filing  
10/8/2013Cooper Collinsmajor shareholderSell23,364$2.47$57,709.08View SEC Filing  
10/9/2012Michael Cooper PearceDirectorSell1,288$8.00$10,304.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Pernix Therapeutics Holdings (NASDAQ:PTX)
Latest Headlines for Pernix Therapeutics Holdings (NASDAQ:PTX)
DateHeadline logoPernix Therapeutics (PTX) Reports Prelim. Q2 Revenue of $33M-$35M - July 21 at 6:27 AM logoPernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results - July 21 at 6:27 AM logoPernix Commences Refinancing Transactions to Fortify Balance Sheet - July 21 at 6:27 AM logoGainers & Losers Of July 13: PTX, ALDR, MNKD, TSRO, TOCA... - July 14 at 7:42 AM logoBreakfast Technical Briefing on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, Pernix Therapeutics, and ... - PR Newswire (press release) - July 11 at 6:52 AM logoPernix Therapeutics Holdings, Inc. (PTX) Rating Lowered to Strong Sell at ValuEngine - July 8 at 10:10 PM logoPernix Therapeutics Added to Russell Microcap® Index - June 29 at 6:20 AM logoETFs with exposure to Pernix Therapeutics Holdings, Inc. : June 13, 2017 - June 13 at 7:29 PM logoPernix Therapeutics Holdings, Inc. (PTX) Short Interest Update - June 11 at 10:52 PM logoETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 31, 2017 - May 31 at 12:58 PM logoEdited Transcript of PTX earnings conference call or presentation 15-May-17 8:30pm GMT - May 21 at 6:25 PM logoPernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 - May 19 at 12:12 PM logoEarnings Reaction History: Pernix Therapeutics Holdings, Inc., 44.4% Follow-Through Indicator, 11.8% Sensitive - Nasdaq - May 17 at 8:22 AM logoPre-Open Movers 05/16: (AKBA) (ETSY) (SINA) Higher; (PTX) (DKS) (SSYS) Lower (more...) - May 16 at 7:03 PM logoETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 16, 2017 - May 16 at 7:03 PM logoPernix Therapeutics Holdings Inc (PTX) Announces Quarterly Earnings Results, Beats Estimates By $1.86 EPS - May 16 at 1:34 PM logoBRIEF-Pernix Therapeutics qtrly loss per share $2.94 - May 16 at 9:41 AM logoInvestor Network: Pernix Therapeutics Holdings, Inc. to Host Earnings Call - May 15 at 6:38 PM logoPernix Therapeutics Reports First Quarter 2017 Financial Results and Provides Business Update - May 15 at 6:38 PM logoPernix Therapeutics to Report First Quarter 2017 Financial Results on Monday, May 15 - May 8 at 6:45 PM logoETFs with exposure to Pernix Therapeutics Holdings, Inc. : May 4, 2017 - May 4 at 7:36 PM logoPernix Therapeutics Holdings (PTX) Given Daily News Impact Score of 0.56 - May 2 at 4:20 PM logoPernix Therapeutics Provides Update on Availability of Zohydro® ER with BeadTek™ 20mg Strength - May 1 at 11:05 AM logoSomewhat Negative Media Coverage Very Likely to Affect Pernix Therapeutics Holdings (PTX) Stock Price - April 26 at 1:46 PM logoRennova Health and Pernix Therapeutics Both Led In the Pharma Arena with Significant Share Price Jumps - Yahoo Finance - April 24 at 2:32 PM logoPernix Therapeutics Holdings (PTX) Receiving Critical News Coverage, AlphaOne Reports - April 23 at 9:05 AM logoETFs with exposure to Pernix Therapeutics Holdings, Inc. : April 19, 2017 - April 19 at 7:21 PM logoPlatinex Inc.-Proposed Private Placement - April 18 at 6:40 PM logoCritical Media Coverage Very Likely to Effect Pernix Therapeutics Holdings (PTX) Share Price - April 15 at 12:09 PM logoETFs with exposure to Pernix Therapeutics Holdings, Inc. : April 7, 2017 - April 7 at 7:43 PM logoPernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017 - April 7 at 12:05 PM logoEdited Transcript of PTX earnings conference call or presentation 28-Mar-17 8:30pm GMT - March 29 at 8:55 AM logoPernix Therapeutics Holdings Inc (PTX) Short Interest Down 22.7% in March - March 29 at 8:11 AM logoPernix Therapeutics Holdings (PTX) Jumps with Q4 Earnings on Way - March 28 at 7:12 PM logoPernix Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results - March 28 at 7:12 PM logoPERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 10-K, Annual Report - March 28 at 7:12 PM logoEarnings Scheduled For March 28, 2017 - Benzinga - March 28 at 9:37 AM logo25 Stocks Moving In Tuesday's Pre-Market Session - Benzinga - March 28 at 9:37 AM logoQ4 2016 Pernix Therapeutics Holdings Inc Earnings Release - After Market Close - March 28 at 9:37 AM logoPernix Therapeutics Holdings Inc (PTX) Set to Announce Earnings on Tuesday - March 27 at 7:23 AM logoAn Investor's Rationale To Staying Long Pernix Therapeutics - March 24 at 7:14 PM logoPernix: An Investor's Rationale to Staying Long - March 23 at 7:50 PM logoPernix Therapeutics (PTX) and GlaxoSmithKline (GSK) Amend ... - - March 23 at 12:19 AM logoPernix Therapeutics (PTX) and GlaxoSmithKline (GSK) Amend Interim Settlement Agreement - March 21 at 7:08 PM logoPernix Therapeutics to Report Fourth Quarter and Year-End 2016 Financial Results on Tuesday, March 28 - GlobeNewswire (press release) - March 16 at 12:34 AM logo20 Stocks Moving In Monday's Pre-Market Session | Benzinga - Benzinga - March 6 at 6:45 PM logoPre-Market Most Active for Feb 23, 2017 : CNHI, CLD, CHK, BAC, TSLA, BSX, LB, PTX, CTRP, NVDA, ERIC, TVIX - Nasdaq - February 24 at 8:17 AM logoPernix Therapeutics Prevails in Zohydro® ER ANDA Litigation - GlobeNewswire (press release) - February 24 at 8:17 AM logo8:02 am Pernix Therapeutics confirmed received favorable opinion in its litigation with Actavis Laboratories FL, Inc. regarding a proposed generic version of Zohydro ER - February 24 at 12:31 AM logoPernix Therapeutics (PTX) Wins Zohydro ER ANDA Litigation - February 23 at 7:29 PM



Pernix Therapeutics Holdings (PTX) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by Staff